This article is an erratum on:
Advances in RIPK1 kinase inhibitors
Frontiers Production Office*An Erratum on
Advances in RIPK1 kinase inhibitors
by Chen L, Zhang X, Ou Y, Liu M, Yu D, Song Z, Niu L, Zhang L and Shi J (2022). Front. Pharmacol. 13:976435. doi: 10.3389/fphar.2022.976435
Due to a production error, the list of affiliations used for the authors was incorrect. The correct affiliations list is shown below.
Lu Chen1,2,†, Xiaoqin Zhang3,†, Yaqing Ou4,†, Maoyu Liu1,2,†, Dongke Yu1,2, Zhiheng Song5, Lihong Niu6,*, Lijuan Zhang1,2,* and Jianyou Shi1,2,*
1Department of Pharmacy, Sichuan Academy of Medical Sciences & Sichuan Provincial People’s Hospital, School of Medicine, University of Electronic Science and Technology of China, Chengdu, China
2Personalized Drug Therapy Key Laboratory of Sichuan Province, School of Medicine, University of Electronic Science and Technology of China, Chengdu, China
3Department of Critical Care Medicine, Sichuan Academy of Medical Sciences & Sichuan Provincial People’s Hospital, Affiliated Hospital of University of Electronic Science and Technology of China, Chengdu, Sichuan, China
4Department of Pharmacy, The Affiliated Chengdu 363 Hospital of Southwest Medical University, Chengdu, Sichuan, China
5Suzhou University of Science and Technology, Suzhou, Jiangsu, China, 6 Institute of Laboratory Animal Sciences, Academy of Medical Sciences and Sichuan Provincial People’s Hospital, Chengdu, Sichuan, China
The publisher apologizes for this mistake. The original version of this article has been updated.
Keywords: inhibitor, receptor interacting protein 1 (RIP1), programmed necrosis, necrosis, RIP1 (RIPK1)
Citation: (2023) Erratum: Advances in RIPK1 kinase inhibitors. Front. Pharmacol. 13:1123234. doi: 10.3389/fphar.2022.1123234
Received: 13 December 2022; Accepted: 13 December 2022;
Published: 09 January 2023.
Approved by:
Frontiers Editorial Office, Frontiers Media SA, SwitzerlandCopyright © 2023 Frontiers Production Office. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Frontiers Production Office, production.office@frontiersin.org